Dr. Kang on Aprepitant for Preventing CINV in Children

July 3, 2014
Hyoung Jin Kang, MD, PhD

Hyoung Jin Kang, MD, PhD, associate professor, Department of Pediatrics, Seoul National University, South Korea, discusses a phase III trial of aprepitant for chemotherapy-induced nausea and vomiting (CINV) in children.

Hyoung Jin Kang, MD, PhD, associate professor, Department of Pediatrics, Seoul National University, South Korea, discusses a phase III trial of aprepitant for chemotherapy-induced nausea and vomiting (CINV) in children. This study was presented at the 2014 MASCC/ISOO International Symposium.

Patients aged 12-17 undergoing emetogenic chemotherapy were randomized to receive aprepitant capsule 125 mg and ondansetron before chemotherapy (on day 1) and aprepitant capsule 80 mg (on days 2-3) or placebo (on days 1-3) plus ondansetron (on day 1). A total of 302 patients were evaluated.

Researchers concluded that the drug combination with aprepitant was well tolerated and more effective in preventing CINV. Kang says these data can be practice-changing for supportive care for pediatric patients.